Pomegra
Rightway Healthcare closes a $155M round, pushing total funding to $394.3M as its transparent pharmacy benefits model finds traction with employers caught between rising drug costs and conflicted incumbents.
Key Takeaways
- Rightway Healthcare's latest round of $155M brings lifetime funding to $394.3M, with six undisclosed investors backing the deal.
- The company serves roughly 2 million employees through clients including Tyson, eBay, and Qualtrics, targeting the $600B PBM market.
- Rightway was last publicly valued at $1.1 billion in its 2021 Series C; no new valuation has been disclosed for this round.
Lead
Rightway Healthcare, the New York-based care navigation and pharmacy benefits management startup, closed a $155 million financing round in September 2026, according to a U.S. Securities and Exchange Commission filing. Six investors participated; none have been named. The round arrived without a press release - a quieter milestone than the company's prior fundraises, but a significant one given the scale. Founders Jordan Feldman and Theodore Feldman have now raised nearly $400 million since launching the company in 2017.
What Does Rightway Actually Do?
Rightway pairs two services that employers typically buy separately: a care navigation platform that assigns dedicated clinical guides to plan members, and RightwayRx, a proprietary pharmacy benefits manager (PBM) designed to cut out the opacity baked into legacy drug benefit arrangements. The conventional PBM market - dominated by CVS Caremark, OptumRx, and Express Scripts - runs on manufacturer rebate systems that critics argue inflate list prices while generating undisclosed profits for intermediaries. Rightway's pitch is simpler and blunter: show employers where the money actually goes.
The company added Care Complete Weight Management in April 2026, specifically targeting employer spending on GLP-1 medications such as semaglutide. Demand for those drugs is compressing benefits budgets across industries, and Rightway is selling clinical steerage alongside benefit administration as a single-vendor answer. In January 2026, it launched SureSpend, a pricing transparency product that locks in pharmacy costs and eliminates the retroactive adjustments common in traditional PBM contracts.
Why Did Investors Back Another Round?
Context for the conviction: the PBM sector is under simultaneous pressure from regulators, Congress, and employers. The Federal Trade Commission has released damaging reports on rebate-driven pricing. Multiple Congressional proposals have targeted spread pricing and rebate opacity. Employer healthcare costs, meanwhile, have grown faster than wages for years running, creating a receptive audience for any credible alternative.
Rightway has real revenue proof to show. The company ranked #42 on the 2025 Deloitte Technology Fast 500, a list of North America's fastest-growing tech firms. Those aren't a startup's aspirational numbers - they are growth metrics that make a late-stage fundraise defensible in a market where digital health investors are considerably more selective than they were three years ago.
The company was incubated with Thrive Capital in 2019 and has attracted backing from Khosla Ventures, which led the 2021 Series C at a $1.1 billion valuation, as well as Tiger Global Management. Whether those firms participated in this round has not been disclosed.
Strategic Context
The employer-sponsored insurance market is the core target. Roughly 160 million Americans get health coverage through an employer, and those employers collectively spend enormous sums on drug benefits administered by a handful of firms with deeply entrenched contracts. Switching PBMs is operationally difficult, which is precisely why the disruption cycle runs slow and requires sustained capital to fund the sales cycle and client implementation.
Rightway's growth to 2 million covered lives - with employer clients spanning manufacturing (Tyson), technology (eBay, Qualtrics), and other sectors - demonstrates a multi-vertical capability. But 2 million is still a fraction of a market measured in hundreds of millions of lives. The gap between current scale and transformative scale is exactly the kind of problem a $155 million check is designed to close.
What Comes Next for Rightway?
The absence of a named lead investor and a disclosed valuation means the round's structure is not fully readable from the outside. In the current environment, that could reflect a bridge extension from existing investors, a new strategic backer with confidentiality requirements, or a more traditional institutional round still in the process of being finalized publicly. What the SEC filing confirms is that capital is coming in, and at a meaningful size.
Product expansion in GLP-1 management and continued employer customer acquisition appear to be the clearest near-term priorities. The company's rebrand in September 2025 signaled a deliberate effort to reposition from a point-solution vendor to a comprehensive health spending platform.
Outlook
Rightway enters late 2026 better capitalized than at any prior point, with product lines directly addressing the most acute employer benefits pain points of the moment. The structural challenge remains unchanged: the three dominant PBMs hold contracts that are sticky, complex to exit, and backed by distribution infrastructure that no startup can replicate quickly. Nearly $400 million in total funding provides the runway to chip away at that advantage through employer acquisition and clinical outcomes, but the timeline to meaningful market-share disruption is measured in years, not quarters.
